UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.
Also called NCT07163624
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 211 participants
- Registry
-
NCT07163624
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT07163624. Randomized; double masking; primary purpose treatment. Start 2025-03-22 (actual); primary completion 2025-11-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
- Acronym
- T2DM
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug)
- UBT251 Injection 2.0 mg and UBT251 Injection Placebo
- Intervention (Drug)
- UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo
- Intervention (Drug)
- UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo
- Intervention (Drug)
- UBT251 Injection 6.0 mg and UBT251 Injection Placebo
- Intervention (Drug)
- Semaglutide Injection (Ozempic®)
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Record details
- Record id
cardio:ct-nct07163624- Content hash
97c13ef69e148ce0a30bb037f55d6471f9d495d30fcc5e3f27ecb2b23468a606